CN102319224A - 复方甲氧那明的速释-缓释渗透泵制剂 - Google Patents
复方甲氧那明的速释-缓释渗透泵制剂 Download PDFInfo
- Publication number
- CN102319224A CN102319224A CN201110211128A CN201110211128A CN102319224A CN 102319224 A CN102319224 A CN 102319224A CN 201110211128 A CN201110211128 A CN 201110211128A CN 201110211128 A CN201110211128 A CN 201110211128A CN 102319224 A CN102319224 A CN 102319224A
- Authority
- CN
- China
- Prior art keywords
- cellulose
- tablet
- release
- layer
- osmotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003204 osmotic effect Effects 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 229960005405 methoxyphenamine Drugs 0.000 title claims abstract description 14
- OEHAYUOVELTAPG-UHFFFAOYSA-N methoxyphenamine Chemical compound CNC(C)CC1=CC=CC=C1OC OEHAYUOVELTAPG-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 title claims description 8
- 239000003814 drug Substances 0.000 claims abstract description 31
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 claims abstract description 22
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 22
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 claims abstract description 22
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960003556 aminophylline Drugs 0.000 claims abstract description 22
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 210000002784 stomach Anatomy 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 43
- 239000004615 ingredient Substances 0.000 claims description 41
- 229920002678 cellulose Polymers 0.000 claims description 34
- 239000012528 membrane Substances 0.000 claims description 34
- 239000001913 cellulose Substances 0.000 claims description 33
- 235000010980 cellulose Nutrition 0.000 claims description 33
- -1 hydroxypropyl Chemical group 0.000 claims description 29
- 238000000576 coating method Methods 0.000 claims description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- 239000002671 adjuvant Substances 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 20
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 18
- 239000011230 binding agent Substances 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000011248 coating agent Substances 0.000 claims description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 13
- 229960000659 methoxyphenamine hydrochloride Drugs 0.000 claims description 13
- FGSJNNQVSUVTPW-UHFFFAOYSA-N methoxyphenamine hydrochloride Chemical compound Cl.CNC(C)CC1=CC=CC=C1OC FGSJNNQVSUVTPW-UHFFFAOYSA-N 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 10
- 229920002301 cellulose acetate Polymers 0.000 claims description 10
- 239000003086 colorant Substances 0.000 claims description 10
- 239000000314 lubricant Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 235000002639 sodium chloride Nutrition 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 229920006218 cellulose propionate Polymers 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 229920002635 polyurethane Polymers 0.000 claims description 6
- 239000004814 polyurethane Substances 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000010603 pastilles Nutrition 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000001384 succinic acid Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- BAZVSMNPJJMILC-UHFFFAOYSA-N triadimenol Chemical compound C1=NC=NN1C(C(O)C(C)(C)C)OC1=CC=C(Cl)C=C1 BAZVSMNPJJMILC-UHFFFAOYSA-N 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 238000003475 lamination Methods 0.000 claims description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 2
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims description 2
- 229920001747 Cellulose diacetate Polymers 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 2
- FNJSWIPFHMKRAT-UHFFFAOYSA-N Monomethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(O)=O FNJSWIPFHMKRAT-UHFFFAOYSA-N 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- ZGJVTOHMNLDNNU-UHFFFAOYSA-N acetic acid;heptanoic acid Chemical compound CC(O)=O.CCCCCCC(O)=O ZGJVTOHMNLDNNU-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000013877 carbamide Nutrition 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 235000019800 disodium phosphate Nutrition 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- 229910000765 intermetallic Inorganic materials 0.000 claims description 2
- 230000002045 lasting effect Effects 0.000 claims description 2
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 2
- 235000011151 potassium sulphates Nutrition 0.000 claims description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- OKUCEQDKBKYEJY-UHFFFAOYSA-N tert-butyl 3-(methylamino)pyrrolidine-1-carboxylate Chemical compound CNC1CCN(C(=O)OC(C)(C)C)C1 OKUCEQDKBKYEJY-UHFFFAOYSA-N 0.000 claims description 2
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 claims description 2
- 229940070710 valerate Drugs 0.000 claims description 2
- 229940005605 valeric acid Drugs 0.000 claims description 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 abstract 1
- 150000003840 hydrochlorides Chemical class 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 40
- 238000003756 stirring Methods 0.000 description 28
- 239000008187 granular material Substances 0.000 description 16
- 238000007908 dry granulation Methods 0.000 description 8
- 239000008240 homogeneous mixture Substances 0.000 description 8
- 238000007873 sieving Methods 0.000 description 8
- 238000005550 wet granulation Methods 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 4
- 238000007580 dry-mixing Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229940124584 antitussives Drugs 0.000 description 3
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000009492 tablet coating Methods 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940071462 oralone Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002951 street drug Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
Abstract
本发明公开一类含有药物成分为甲氧那明或其盐酸盐、那可丁、氨茶碱、马来酸氯苯那敏的速释-缓释渗透泵片剂,其特征在于该制剂包含两个释药部分,一部分为速释部分,含有1-70%的有效成分,包裹于渗透泵片剂表面,使得药物在进入胃部可快速释放;另一部分为缓释部分,含有30-99%的有效成分,包含于渗透泵片剂内部,控制药物的持续释放可达8小时至24小时。
Description
技术领域
本发明涉及一类含有药物成分为甲氧那明或其盐酸盐、那可丁、氨茶碱、马来酸氯苯那敏,1-70%为速释制剂,99-30%为缓释制剂的渗透泵片剂。其特征在于该制剂包含两个释药部分,一部分为速释部分,包裹于渗透泵片剂表面,使得药物在进入胃部可快速释放;另一部分为缓释部分,包含于渗透泵片剂内部,控制药物的持续释放可达8小时至24小时。
背景技术
复方甲氧那明为平喘药,用于支气管哮喘和喘息性支气管炎。盐酸甲氧那明可抑制支气管痉挛,缓解哮喘发作时的咳嗽。那可丁为外周性止咳药,可抑制咳嗽。氨茶碱亦可抑制支气管痉挛,还可抑制支气管粘膜肿胀,缓解哮喘发作时的咳嗽,使痰易咳出。马来酸氯苯那敏具抗组胺作用。本品的配伍不仅可以减轻咽喉及支气管炎症等引起的咳嗽,而且可缓解哮喘发作时的咳嗽,有利于排痰。目前复方甲氧那明产品的服用方法为口服一次2粒,一日3次。
中国专利200410065967.4公布了含有甲氧那明、那可丁、氨茶碱、马来酸氯苯那敏的口服固体制剂的制备方法,使用该方法制得的复方甲氧那明产品不具备缓释释放的功效。按照现有的市售药品服用方法,不仅服用剂量较大,而且服用次数多,不利于保障病患者按时吃药。长效缓释制剂可以弥补速释制剂的缺陷。但是单纯的普通长效缓释制剂虽能维持长时间的药效,但有起效慢、血药浓度峰谷现象、释药速率易受胃肠道环境因素(如PH值、胃肠道蠕动等)影响的缺点。而平喘止咳药有迅速起效缓解病患症状、并能稳定维持长时间的药效的需求。渗透泵长效缓释制剂能够使药物以零级速度释放、相对于普通制剂药物恒速释放时间明显延长(通常为12~24小时)、释药速度不受胃肠蠕动、pH、胃排空时间等因素影响的优点。基于现有制剂产品的缺点以及平喘止咳药既要起效快,又要维持长效的需求,本发明提供了一种将有效成分1-70%为速释制剂,99-30%为缓释制剂,缓释释放达8至24小时的复方甲氧那明的速释-缓释渗透泵制剂。本发明可实现药物迅速发挥药 效,且能维持药效达8至24小时。
发明内容
本发明的目的是提供一种有效成分为甲氧那明或其盐酸盐、那可丁、氨茶碱、马来酸氯苯那敏的速释-缓释渗透泵固体制剂。
本发明的目的可以通过以下措施来达到:
有效成分为甲氧那明或其盐酸盐、那可丁、氨茶碱、马来酸氯苯那敏。本发明的速释功效来源于速释部分,其组成为有效成分本身,或是与其它可选的辅料制成的混合物;本发明的缓释功效来源于速释-缓释制剂的缓释部分,其特征为缓释部分为渗透泵片,包含含药层和助推层。
其缓释部分即渗透泵片包含有效成分、功能性辅料及可选辅料。有效成分是指甲氧那明或其盐酸盐、那可丁、氨茶碱和马来酸氯苯那敏,功能性辅料包含半透膜材料、助推剂、混悬剂和渗透压活性剂中的一种或几种;并包含或不包含其它辅料,其他辅料包括:填充剂、粘合剂、增塑剂、着色剂、润滑剂。所述的半透膜材料是指:纤维素酯类,纤维素醚类和纤维素酯-醚类如醋酸纤维素、二醋酸纤维素、三醋酸纤维素、丙酸纤维素、醋酸丙酸纤维素、醋酸丁酸纤维素、三戊酸纤维素、对三醋酸纤维素、三棕榈酸酯纤维素、纤维素三辛酰酯、三丙酸纤维素、二琥珀酸纤维素、二棕榈酸酯纤维素、纤维素二辛酰酯、纤维素二辛酸酯、醋酸戊酸纤维素,琥珀酸醋酸纤维素、琥珀酸丙酸纤维素、醋酸辛酸纤维素、戊酸棕榈酸酯纤维素、醋酸庚酸纤维素、乙二甲缩醛纤维素;聚氨基甲酸乙酯醋酸纤维素;聚氨基甲酸甲酯醋酸纤维素;二甲氨酸乙酸酯纤维素;聚酰胺半透膜;聚氨酯半透膜;磺化聚苯乙烯半透膜;乙基纤维素等其中的一种或几种;混悬剂是指:羟丙基纤维素、羟乙基纤维素、羟丙基甲基纤维素、聚乙烯吡咯烷酮、聚乙二醇、羟丙乙基纤维素、羟丙丁基纤维素、羟丙戊基纤维素、海藻酸钠、羟丙基甲基纤维素、聚乙烯、聚环氧乙烷、聚氧乙烯、阿拉伯胶、羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠、聚乙烯吡咯烷酮、卡波普等其中的一种或几种;渗透压活性剂是指:氯化钠、氯化钾、硫酸镁、硫酸钠、乳糖、果糖、甘露醇、葡萄糖、蔗糖、磷酸氢二钠、氯化锂、氯化镁、硫酸钾、硫酸锂、磷酸钾、尿素、肌醇、琥珀酸镁、酒石酸、棉籽糖,山梨糖、无机盐、有机盐和糖类等其中的一种或几种;助推剂是指:高分子量聚环氧乙烷、交联羧甲基纤维素碱;聚丙烯酸(如商品名为 的聚丙烯酸),分子量在80000至200000;丙烯酸多糖聚合物(如聚葡萄糖,商品名为 聚丙烯酸葡萄糖二酯);聚丙烯酰胺(商品名为 )、羧甲基淀粉钠、乙醇淀粉钠、交联羧甲基纤维素钠、交联吡咯烷酮、低取代羟丙甲基纤维素等其中的一种或几种;填充剂是指:微晶纤维素、二氧化硅化微晶纤维素、乳糖、淀粉、预胶化淀粉、磷酸氢钙、碳酸钙、甘露醇、果糖、蔗糖等其中的一种或几种;粘合剂是指:聚乙烯吡咯烷酮、纤维素类衍生物如羟甲基纤维素钠等、淀粉及预胶化淀粉等其中的一种或几种;增塑剂是指:聚乙二醇、邻苯二甲酸甲酯、邻苯二甲酸乙酯、邻苯二甲酸丁酯、柠檬酸三乙酯、柠檬酸酯等其中的一种或几种;着色剂是指:各种天然及合成色淀、金属化合物如氧化铁红等其中的一种或几种;润滑剂是指:二氧化硅、滑石粉、硬脂酸、硬脂酸镁、硬脂富马酸钠、山嵛酸甘油酯等其中的一种或几种。
本发明所述的复方速释-缓释渗透泵片制剂的制备方法如下:
片剂制备方法一:
1.片剂为渗透泵片,由缓释片芯、半透膜材料包衣层、速释药层、和可选的普通薄膜包衣层组成;
2.缓释片芯为渗透泵片,包含有效成分(盐酸甲氧那明、那可丁、氨茶碱、马来酸氯苯那敏);含有助推剂、混悬剂、渗透压活性剂等辅料中的一种或几种,并包含或不包含其它辅料,其它辅料包括:填充剂、粘合剂、润滑剂和着色剂;将该缓释片芯物料压制成片剂;
3.将由2)制得的片剂以半透膜材料包衣;
4.在半透膜衣膜上以激光或者机械方法在一面或者双面打一个或多个释药孔;
5.将速释部分的有效成分和粘合剂溶于溶剂中,配制成含有有效成分的溶液,用该溶液将有效成分包裹于上述打好孔的渗透泵片表面;
6.可选的,将上述制备完成的渗透泵片包普通薄膜衣。
片剂制备方法二:
1.片剂为渗透泵片,由片芯、半透膜材料包衣层、速释药层、和可选的普通薄膜包衣层组成;
2.片芯包含一层助推层和一层含药层;含药层含有效成分(盐酸甲氧那明、那可丁、氨茶碱、马来酸氯苯那敏);助推层含有助推剂、混悬剂、渗透压活性剂中的一种或几种;并且片芯包含或不包含其它辅料,其它辅料包括:填充剂、粘合剂、润滑剂和着色剂;将含药层和助推层压制成双层片;
3.将由含药层和助推层制成的双层片剂以半透膜材料包衣;
4.在含药侧的半透膜衣膜上以激光或者机械方法打一个或多个释药孔;
5.将速释部分的有效成分和粘合剂溶于溶剂中,配制成含有有效成分的溶液,用该溶液将有效成分包裹于上述打好孔的渗透泵片表面。
6.可选的,将上述制备完成的渗透泵片包普通薄膜衣。
片剂制备方法三:
1.片剂为渗透泵片,由片芯、半透膜材料包衣层、速释药层、和可选的普通薄膜包衣层组成;
2.片芯包含一层助推层和两层含药层;含药层含有效成分(盐酸甲氧那明、那可丁、氨茶碱、马来酸氯苯那敏);助推层含有助推剂、混悬剂、渗透压活性剂中的一种或几种;并包含或不包含其它辅料,其它辅料包括:填充剂、粘合剂、润滑剂和着色剂;将两层含药层和一层助推层压制成中间为助推层、上下为含药层的三层片剂
3.将由含药层和助推层制成的三层片剂以半透膜材料包衣;
4.在含药两侧的半透膜衣膜上以激光或者机械方法各打一个或多个释药孔;
5.将速释部分的有效成分和粘合剂溶于溶剂中,配制成含有有效成分的溶液,用该溶液将有效成分包裹于上述打好孔的渗透泵片表面。
6.可选的,将上述制备完成的渗透泵片包普通薄膜衣。
附图说明
图1表示实施例1所得速释-缓释渗透泵片剂的溶出度曲线图;
图2表示实施例2所得速释-缓释渗透泵片剂的溶出度曲线图。
具体实施方式
下面列举一些具体实施例对本发明做进一步详细的说明,但不仅仅局限于下述实施例:
实施例1:
制备工艺:
按照上述配方量的比例,用干混,或干法制粒,或湿法制粒工艺制成片芯含药层混合物。
干混工艺制备方法:将有效成分(盐酸甲氧那明、那可丁、氨茶碱、马来酸氯苯那敏)加入聚氧乙烯N80,搅拌均匀;加入硬脂酸镁,搅拌成均匀制成片芯含药层混合物。
干法制粒工艺制备方法:将有效成分(盐酸甲氧那明、那可丁、氨茶碱、马来酸氯苯那敏)加入聚氧乙烯N80,搅拌制成均匀混合物,将上述混合物挤压成片状或块状物;再将所述片状或块状物粉碎,使之能全部通过中国药典二号筛;过筛后的颗粒加入硬脂酸镁,搅拌均匀;制成片芯含药层混合物。
湿法制粒工艺制备方法:将有效成分(盐酸甲氧那明、那可丁、氨茶碱、马来酸氯苯那敏)加入聚氧乙烯N80,搅拌制成均匀混合物,在混合物中加入适量的乙醇溶液,搅拌制成颗粒并烘干;再将烘干后的颗粒粉碎,使之能全部通过中国药典二号筛;过筛后的颗粒加入硬脂酸镁,搅拌均匀;制成片芯含药层混合物。
按照上述配方量的比例,用干混,或干法制粒,或湿法制粒工艺制成片芯助推层混合物。
干混工艺制备方法:将聚氧乙烯WSR301、氯化钠、氧化铁混合,搅拌均匀;加入硬脂酸镁,搅拌成均匀制成片芯助推层混合物。
干法制粒工艺制备方法:将聚氧乙烯WSR301、氯化钠、氧化铁混合,搅拌制成均匀混合物,将上述混合物挤压成片状或块状物;再将所述片状或块状物粉碎,使之能全部通过中国药典二号筛;过筛后的颗粒加入硬脂酸镁,搅拌均匀;制成片芯助推层混合物。
湿法制粒工艺制备方法:将聚氧乙烯WSR301、氯化钠、氧化铁混合,搅拌制成均匀混合物;在混合物中加入适量的水或乙醇溶液,搅拌制成颗粒并烘干;再将烘干后的颗粒粉碎,使之能全部通过中国药典二号筛;过筛后的颗粒加入硬脂酸镁,搅拌均匀;制成片芯助推层混合物。
将片芯含药层混合物等分成2份,和片芯助推层混合物采用特定的三层片压片机,压制成三层药片,其中含药层在上下两层,中间为助推层;
将醋酸纤维素和聚乙二醇加入丙酮和乙醇比例为3∶1的溶剂中,配制成半透膜包衣溶液。将上述由含药层和助推层制成的三层片剂以半透膜材料包衣;
在两侧含药层的半透膜衣膜上以激光或者机械方法打一直径为0.8mm的释药孔;
将速释部分的有效成分和羟丙甲基纤维素溶于水或者乙醇溶剂中,配制成含有有效成分的包衣溶液,用该溶液包裹于将上述打好孔的渗透泵片的表面。
将欧巴代II溶于水中,配制成薄膜衣包衣溶液,用该溶液将上述渗透泵片包衣。
实施例2:
制备工艺:
按照上述配方量的比例,用干混,或干法制粒,或湿法制粒工艺制成片芯含药层混合物。
干混工艺制备方法:将有效成分(盐酸甲氧那明、那可丁、氨茶碱、马来酸氯苯那敏)加入聚氧乙烯N80,搅拌均匀;加入硬脂酸镁,搅拌成均匀制成片芯含药层混合物。
干法制粒工艺制备方法:将有效成分(盐酸甲氧那明、那可丁、氨茶碱、马来酸氯苯那敏)加入聚氧乙烯N80,搅拌制成均匀混合物,将上述混合物挤压成片状或块状物;再将所述片状或块状物粉碎,使之能全部通过中国药典二号筛;过筛后的颗粒加入硬脂酸镁,搅拌均匀;制成片芯含药层混合物。
湿法制粒工艺制备方法:将有效成分(盐酸甲氧那明、那可丁、氨茶碱、马来酸氯苯那敏)加入聚氧乙烯N80,搅拌制成均匀混合物,在混合物中加入适量的乙醇溶液,搅拌制成颗粒并烘干;再将烘干后的颗粒粉碎,使之能全部通过中国药典二号筛;过筛后的颗粒加入硬脂酸镁,搅拌均匀;制成片芯含药层混合物。
按照上述配方量的比例,用干混,或干法制粒,或湿法制粒工艺制成片芯助推层混合物。
干混工艺制备方法:将聚氧乙烯WSR301、氯化钠、氧化铁混合,搅拌均匀;加入硬脂酸镁,搅拌成均匀制成片芯助推层混合物。
干法制粒工艺制备方法:将聚氧乙烯WSR301、氯化钠、氧化铁混合,搅拌制成均匀混合物,将上述混合物挤压成片状或块状物;再将所述片状或块状物粉碎,使之能全部通过中国药典二号筛;过筛后的颗粒加入硬脂酸镁,搅拌均匀;制成片芯助推层混合物。
湿法制粒工艺制备方法:将聚氧乙烯WSR301、氯化钠、氧化铁混合,搅拌制 成均匀混合物;在混合物中加入适量的水或乙醇溶液,搅拌制成颗粒并烘干;再将烘干后的颗粒粉碎,使之能全部通过中国药典二号筛;过筛后的颗粒加入硬脂酸镁,搅拌均匀;制成片芯助推层混合物。
将片芯含药层混合物和片芯助推层混合物采用特定的双层压片机,压制成双层药片;
将醋酸纤维素和聚乙二醇加入丙酮和乙醇比例为3∶1的溶剂中,配制成半透膜包衣溶液。将上述由含药层和助推层制成的双层片剂以半透膜材料包衣;
在含药层一侧的半透膜衣膜上以激光或者机械方法打一直径为0.8mm的释药孔;
将速释部分的有效成分和羟丙甲基纤维素溶于水或者乙醇溶剂中,配制成含有有效成分的包衣溶液,用该溶液包裹于将上述打好孔的渗透泵片的表面。
将欧巴代II溶于水中,配制成薄膜衣包衣溶液,用该溶液将上述渗透泵片包衣。
Claims (9)
1.一种复方甲氧那明的速释-缓释渗透泵片剂,其有效成分为甲氧那明或其盐酸盐、那可丁、氨茶碱、马来酸氯苯那敏,其特征在于该片剂包含两个释药部分,一部分为速释部分,包裹于渗透泵片剂表面,使得药物在进入胃部可快速释放;另一部分为缓释部分,包含于渗透泵片剂内部,控制药物的持续释放可达8小时至24小时。
2.根据权利要求1所述的速释-缓释渗透泵片剂,其特征在于速释部分含有1-70%的有效成分,缓释部分含有30-99%的有效成分。
3.根据权利要求1所述的速释-缓释渗透泵片剂,其速释部分包含有效成分:甲氧那明或其盐酸盐、那可丁、氨茶碱、马来酸氯苯那敏中的一种或几种;并包含或不包含其它辅料,其它辅料包括:填充剂和粘合剂中的一种或几种。
4.根据权利要求1所述速释-缓释渗透泵片剂,其缓释部分包含有效成分和功能性辅料并包含或不包含其它辅料,其中有效成分是指甲氧那明或其盐酸盐、那可丁、氨茶碱和马来酸氯苯那敏,功能性辅料包含半透膜材料、助推剂、混悬剂和渗透压活性剂中的一种或几种;可选辅料包括:填充剂、粘合剂、增塑剂、着色剂和润滑剂中的一种或几种。
5.根据权利要求4要求所述的缓释部分,其特征在于所述的功能性辅料中,半透膜材料是指:醋酸纤维素、二醋酸纤维素、三醋酸纤维素、丙酸纤维素、醋酸丙酸纤维素、醋酸丁酸纤维素、三戊酸纤维素、对三醋酸纤维素、三棕榈酸酯纤维素、纤维素三辛酰酯、三丙酸纤维素、二琥珀酸纤维素、二棕榈酸酯纤维素、纤维素二辛酰酯、纤维素二辛酸酯、醋酸戊酸纤维素,琥珀酸醋酸纤维素、琥珀酸丙酸纤维素、醋酸辛酸纤维素、戊酸棕榈酸酯纤维素、醋酸庚酸纤维素、乙二甲缩醛纤维素;聚氨基甲酸乙酯醋酸纤维素;聚氨基甲酸甲酯醋酸纤维素;二甲氨酸乙酸酯纤维素;聚酰胺半透膜;聚氨酯半透膜;磺化聚苯乙烯半透膜;乙基纤维素中的一种或几种;混悬剂是指:羟丙基纤维素、羟乙基纤维素、羟丙基甲基纤维素、聚乙烯吡咯烷酮、聚乙二醇、羟丙乙基纤维素、羟丙丁基纤维素、羟丙戊基纤维素、海藻酸钠、羟丙基甲基纤维素、聚乙烯、聚环氧乙烷、聚氧乙烯、阿拉伯胶、羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠、聚乙烯吡咯烷酮、卡波普中的一种或几种;渗透压活性剂是指:氯化钠、氯化钾、硫酸镁、硫酸钠、乳糖、果糖、甘露醇、葡萄糖、蔗糖、磷酸氢二钠、氯化锂、氯化镁、硫酸钾、硫酸锂、磷酸钾、尿素、肌醇、琥珀酸镁、酒石酸、棉籽糖,山梨糖中的一种或几种;助推剂是指:高分子量聚环氧乙烷、交联羧甲基纤维素碱;聚丙烯酸;丙烯酸多糖聚合物;聚丙烯酰胺、羧甲基淀粉钠、乙醇淀粉钠、交联羧甲基纤维素钠、交联吡咯烷酮、低取代羟丙甲基纤维素中的一种或几种。
6.根据权利要求5要求所述的缓释部分,其特征在于所述的其它辅料中,填充剂是指:微晶纤维素、二氧化硅化微晶纤维素、乳糖、淀粉、预胶化淀粉、磷酸氢钙、碳酸钙、甘露醇、果糖、蔗糖中的一种或几种;粘合剂是指:聚乙烯吡咯烷酮、纤维素类衍生物、淀粉及预胶化淀粉中的一种或几种;增塑剂是指:聚乙二醇、邻苯二甲酸甲酯、邻苯二甲酸乙酯、邻苯二甲酸丁酯、柠檬酸三乙酯、柠檬酸酯中的一种或几种;着色剂是指:各种天然及合成色淀、金属化合物中的一种或几种;润滑剂是指:二氧化硅、滑石粉、硬脂酸、硬脂酸镁、硬脂富马酸钠、山嵛酸甘油酯中的一种或几种。
7.根据权利要求1-6任一项所述的速释-缓释渗透泵片剂,其特征在于:
1)片剂为渗透泵片,由缓释片芯、半透膜材料包衣层、速释药层、和可选的普通薄膜包衣层组成;
2)缓释片芯为渗透泵片,包含有效成分盐酸甲氧那明、那可丁、氨茶碱和马来酸氯苯那敏;含有助推剂、混悬剂和渗透压活性剂中的一种或几种,并包含或不包含其它辅料,其它辅料包括:填充剂、粘合剂、润滑剂和着色剂;将该缓释片芯物料压制成片剂;
3)将由2)制得的片剂以半透膜材料包衣;
4)在半透膜衣膜上以激光或者机械方法在一面或者双面打一个或多个释药孔;
5)将速释部分的有效成分和粘合剂溶于溶剂中,配制成含有有效成分的溶液,用该溶液将有效成分包裹于上述打好孔的渗透泵片表面;
6)可选的,将上述制备完成的渗透泵片包普通薄膜衣。
8.根据权利要求1-6任一项所述的速释-缓释渗透泵片剂,其特征在于:
1)片剂为渗透泵片,由片芯、半透膜材料包衣层、速释药层、和可选的普通薄膜包衣层组成;
2)片芯包含一层助推层和一层含药层;含药层含有效成分盐酸甲氧那明、那可丁、氨茶碱和马来酸氯苯那敏;助推层含有助推剂、混悬剂和渗透压活性剂中的一种或几种;并且片芯包含或不包含其它辅料,其它辅料包括:填充剂、粘合剂、润滑剂和着色剂;将含药层和助推层压制成双层片;
3)将由含药层和助推层制成的双层片剂以半透膜材料包衣;
4)在含药侧的半透膜衣膜上以激光或者机械方法打一个或多个释药孔;
5)将速释部分的有效成分和粘合剂溶于溶剂中,配制成含有有效成分的溶液,将该溶液以包衣形式包裹于上述打好孔的渗透泵片表面;
6)可选的,将上述制备完成的渗透泵片包普通薄膜衣。
9.根据权利要求1-6任一项所述的速释-缓释渗透泵片剂,其特征在于:
1)片剂为渗透泵片,由片芯、半透膜材料包衣层、速释药层、和可选的普通薄膜包衣层组成;
2)片芯包含一层助推层和两层含药层;含药层含有效成分盐酸甲氧那明、那可丁、氨茶碱和马来酸氯苯那敏;助推层含有助推剂、混悬剂和渗透压活性剂中的一种或几种;并且片芯包含或不包含其它辅料,其它辅料包括:填充剂、粘合剂、润滑剂和着色剂;将两层含药层和一层助推层混合物压制成中间为助推层、上下为含药层的三层片剂;
3)将由含药层和助推层制成的三层片剂以半透膜材料包衣;
4)在含药两侧的半透膜衣膜上以激光或者机械方法各打一个或多个释药孔;
5)将速释部分的有效成分和粘合剂溶于溶剂中,配制成含有有效成分的溶液,将该溶液以包衣形式包裹于上述打好孔的渗透泵片表面;
6)可选的,将上述制备完成的渗透泵片包普通薄膜衣。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011102111289A CN102319224B (zh) | 2011-07-27 | 2011-07-27 | 复方甲氧那明的速释-缓释渗透泵制剂 |
PCT/CN2011/001461 WO2013013351A1 (zh) | 2011-07-27 | 2011-08-30 | 复方甲氧那明的速释-缓释渗透泵制剂 |
PCT/CN2012/001006 WO2013013509A1 (zh) | 2011-07-27 | 2012-07-27 | 复方甲氧那明的速释—缓释渗透泵制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011102111289A CN102319224B (zh) | 2011-07-27 | 2011-07-27 | 复方甲氧那明的速释-缓释渗透泵制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102319224A true CN102319224A (zh) | 2012-01-18 |
CN102319224B CN102319224B (zh) | 2013-03-20 |
Family
ID=45447153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011102111289A Expired - Fee Related CN102319224B (zh) | 2011-07-27 | 2011-07-27 | 复方甲氧那明的速释-缓释渗透泵制剂 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102319224B (zh) |
WO (1) | WO2013013351A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013013351A1 (zh) * | 2011-07-27 | 2013-01-31 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释-缓释渗透泵制剂 |
WO2013013509A1 (zh) * | 2011-07-27 | 2013-01-31 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释—缓释渗透泵制剂 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201702381QA (en) * | 2014-09-26 | 2017-04-27 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660107A (zh) * | 2004-12-29 | 2005-08-31 | 杭州容立医药科技有限公司 | 复方甲氧那明口服固体制剂及其制备方法 |
CN101642444A (zh) * | 2008-08-08 | 2010-02-10 | 鲁南制药集团股份有限公司 | 单硝酸异山梨酯双速渗透泵型控释制剂及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1265793C (zh) * | 2002-11-18 | 2006-07-26 | 杭州容立医药科技有限公司 | 左西替利嗪伪麻黄碱复方口服制剂及制备方法 |
CN101797253B (zh) * | 2010-03-18 | 2011-07-20 | 四川大学 | 一种岩白菜素、盐酸西替利嗪复方口服剂型 |
CN102319224B (zh) * | 2011-07-27 | 2013-03-20 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释-缓释渗透泵制剂 |
-
2011
- 2011-07-27 CN CN2011102111289A patent/CN102319224B/zh not_active Expired - Fee Related
- 2011-08-30 WO PCT/CN2011/001461 patent/WO2013013351A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1660107A (zh) * | 2004-12-29 | 2005-08-31 | 杭州容立医药科技有限公司 | 复方甲氧那明口服固体制剂及其制备方法 |
CN101642444A (zh) * | 2008-08-08 | 2010-02-10 | 鲁南制药集团股份有限公司 | 单硝酸异山梨酯双速渗透泵型控释制剂及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013013351A1 (zh) * | 2011-07-27 | 2013-01-31 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释-缓释渗透泵制剂 |
WO2013013509A1 (zh) * | 2011-07-27 | 2013-01-31 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释—缓释渗透泵制剂 |
Also Published As
Publication number | Publication date |
---|---|
WO2013013351A1 (zh) | 2013-01-31 |
CN102319224B (zh) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2616081C (en) | Gastroretentive formulations and manufacturing process thereof | |
KR20130142168A (ko) | 조정된 방출을 위한 타소시티닙 함유 경구투여용 제제 | |
EA021784B1 (ru) | Фармацевтические композиции с длительным высвобождением | |
EP2510923B1 (en) | Coating composition, solid preparation coated therewith, and method for preparing solid preparation | |
WO2011118453A1 (ja) | 固形製剤 | |
CN101502491B (zh) | 一种地红霉素肠溶制剂 | |
CN104940156A (zh) | 依帕司他肠溶缓释片及其制备方法 | |
CN100393302C (zh) | 难溶性药物组合物渗透泵控释制剂 | |
TR201802207T4 (tr) | Kontrollü Salımlı Farmasötik Bileşim. | |
CN109985016A (zh) | 一种非布司他的控释组合物及其制备方法 | |
CN101422443B (zh) | 非诺贝特渗透泵型控释制剂及其制备方法 | |
CN102319224B (zh) | 复方甲氧那明的速释-缓释渗透泵制剂 | |
JP2005263704A (ja) | 口腔内粘膜フィルム剤 | |
JP2024054132A (ja) | リオチロニンを含む持続放出組成物 | |
CN103550183B (zh) | 一种盐酸曲美他嗪渗透泵控释片及其制备方法 | |
KR20140131205A (ko) | 수용성 활성성분을 함유하는 서방형 약제학적 조성물 | |
EP2968179B1 (en) | Controlled release pharmaceutical dosage forms | |
CN101626755A (zh) | 包含酸不稳定药物的双单元片剂 | |
CN102210688B (zh) | 复方甲氧那明的速释-缓释制剂 | |
CN101708169A (zh) | 一种含丹皮酚活性物质的结肠靶向给药制剂及其制备方法 | |
CN102349903A (zh) | 一种含有左旋氨氯地平和缬沙坦的全新药物组合物及其制备方法 | |
CN115350160A (zh) | 一种帕利哌酮缓释制剂及其制备方法 | |
CN1415287A (zh) | 盐酸氨溴索渗透泵型控释制剂及其制备方法 | |
JP2009280611A (ja) | 口腔内粘膜フィルム剤 | |
CN104225608A (zh) | 源自胖大海的天然膨胀性基质在渗透泵制剂中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130320 |
|
CF01 | Termination of patent right due to non-payment of annual fee |